On 15 May 2020, the US Food and Drug Administration (FDA) approved ripretinib (QINLOCK, Deciphera Pharmaceuticals, LLC.), for adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.
Efficacy was evaluated in INVICTUS (NCT03353753), an international, multicentre, randomised (2:1), double-blind, placebo-controlled trial in 129 patients with GIST who were previously treated with imatinib, sunitinib, and regorafenib. Patients received a kinase inhibitor, ripretinib 150 mg or placebo orally once daily until disease progression or unacceptable toxicity. Crossover was permitted at disease progression for patients randomised to receive placebo.
The major efficacy outcome measure was progression-free survival (PFS) based on assessment by blinded independent central review (BICR) using modified RECIST v1.1 in which lymph nodes and bone lesions were not target lesions and a progressively growing new tumour nodule within a pre-existing tumour mass must meet specific criteria to be considered unequivocal evidence of progression. Additional efficacy outcome measures included overall response rate (ORR) by BICR and overall survival (OS).
The trial demonstrated a statistically significant improvement in PFS for patients in the ripretinib arm compared with those in the placebo arm (hazard ratio [HR] 0.15; 95% confidence interval [CI] 0.09, 0.25; p < 0.0001). The median PFS was 6.3 months (95% CI 4.6, 6.9) for ripretinib compared with 1.0 month (95% CI 0.9, 1.7) for placebo.
The ORR was 9% (95% CI 4.2, 18) in the ripretinib arm compared with 0% (95% CI 0, 8) in the placebo arm, though this difference was not statistically significant.
The median OS in the ripretinib arm was 15.1 months (95% CI 12.3, 15.1) compared with 6.6 months (95% CI 4.1, 11.6) in the placebo arm with a HR of 0.36 (95% CI 0.21, 0.62), though OS was not evaluated for statistical significance as a result of the sequential testing procedure for the secondary endpoints (i.e., PFS, then ORR, then OS).
The most common adverse reactions (≥20%) with ripretinib were alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhoea, decreased appetite, palmar-plantar erythrodysesthesia, and vomiting. Other important risks of ripretinib include new primary cutaneous malignancies, hypertension, and cardiac dysfunction.
The recommended ripretinib dose is 150 mg orally once daily with or without food.
Full prescribing information for QINLOCK is available here.
FDA collaborated with the Australian Therapeutic Goods Administration (TGA) and Health Canada on the review of this application as part of Project Orbis. FDA approved ripretinib three months ahead of schedule. The review of the applications is ongoing for the Australian TGA and Health Canada.
This review used the Real-Time Oncology Review, which streamlined data submission prior to the filing of the entire clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment.
FDA granted this application priority review, fast track, and breakthrough therapy designation. Ripretinib also received orphan drug designation.
Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.